The rapamycin-regulated gene expression signature determines prognosis for breast cancer.

ABSTRACT:

Background

Mammalian target of rapamycin (mTOR) is a serine/threonine kinase involved in multiple intracellular signaling pathways promoting tumor growth. mTOR is aberrantly activated in a significant portion of breast cancers and is a promising target for treatment. Rapamycin and its analogues are in clinical trials for breast cancer treatment. Patterns of gene expression (metagenes) may also be used to simulate a biologic process or effects of a drug treatment. In this study, we tested the hypothesis that the gene-expression signature regulated by rapamycin could predict disease outcome for patients with breast cancer.

Results

Colony formation and sulforhodamine B (IC50 < 1 nM) assays, and xenograft animals showed that MDA-MB-468 cells were sensitive to treatment with rapa

SUBMITTER: Akcakanat A 

PROVIDER: S-EPMC2761377 | biostudies-literature | 2009 Sep

REPOSITORIES: biostudies-literature